ClinicalTrials.gg
CompletedNCT05822830SURMOUNT-5Updated Nov 26, 2025Results posted

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

A Phase 3 interventional study of Tirzepatide and Semaglutide in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
751
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
9th of 104
751 · median 69
Started
2023
with 7 others
Phase 3
26 of 104
7 open now
Registered
13th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 9th largest by enrollment, is one of 8 that started in 2023, is one of 26 in phase 3, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Metabolism and Nutrition
  • Disorder
  • Prediabetes
  • Diet
  • Exercise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of ≥30 kilogram per square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
  • Have a history of at least 1 unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Change in body weight greater than 5 kg within 3 months prior to starting study
  • Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
  • History of pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    15 mg or MTD - Tirzepatide

    Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) for 4 weeks, then the dose was increased by 2.5 mg every 4 weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg) up to 15 mg QW or maximum tolerated dose \[MTD (10 mg or 15 mg)\] until Week 72.

    Drug: Tirzepatide

  • Active comparator
    2.4 mg or MTD - Semaglutide

    Participants received a starting dose of 0.25 mg semaglutide administered SC QW for 4 weeks, then the dose was increased every 4 weeks (0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg) up to 2.4 mg QW or MTD (1.7 mg or 2.4 mg) until Week 72.

    Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Percent change from baseline in body weight was reported. Least Squares (LS) mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Percentage of participants who achieved ≥10% body weight reduction (observed values) was reported.

    Time frame: Week 72

  2. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Percentage of participants who achieved ≥15% body weight reduction (observed values) was reported.

    Time frame: Week 72

  3. Percentage of Participants Who Achieve ≥20% Body Weight Reduction

    Percentage of participants who achieved ≥20% body weight reduction (observed values) was reported.

    Time frame: Week 72

  4. Percentage of Participants Who Achieve ≥25% Body Weight Reduction

    Percentage of participants who achieved ≥25% body weight reduction (observed values) was reported.

    Time frame: Week 72

  5. Change From Baseline in Waist Circumference in Centimeter

    Change from baseline in waist circumference in centimeter was reported. LS mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  6. Percentage of Participants Who Achieve ≥30% Body Weight Reduction

    Percentage of participants who achieved ≥30% body weight reduction (observed values) was reported.

    Time frame: Week 72

  7. Change From Baseline in Body Mass Index (BMI)

    Change from baseline in BMI was reported. LS mean was determined using Mixed Model Repeated Measures (MMRM) model using Baseline + Sex + Pre diabetes status at randomization + Treatment + Time + Treatment\*Time(Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

  8. Percent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide

    Percent change from baseline in body weight comparing 15mg of Tirzepatide and 2.4 mg Semaglutide was reported. The treatment effect for tirzepatide versus semaglutide for percent change in body weight was also evaluated assuming that participants had stayed on treatment and reached the highest dose of treatment. LS mean was determined by MMRM model using Baseline + Sex + Pre diabetes status at randomization + Baseline BMI Group 1 + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 72

07

Results

Posted Nov 26, 2025

Participant flow

Participant flow — Overall Study
Milestone15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Started375376
Received at least one dose of study drug374376
Completed319319
Not completed5657
Withdrew: Adverse event66
Withdrew: Assigned treatment by mistake53
Withdrew: Lost to follow-up1618
Withdrew: Non-compliance with study drug11
Withdrew: Participant was out of the country01
Withdrew: Pregnancy12
Withdrew: Withdrawal by subject2726

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Percent change from baseline in body weight was reported. Least Squares (LS) mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent change15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percent Change From Baseline in Body Weight-20.2 ± 0.59-13.7 ± 0.59
Statistical analysis
  • 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide · Ls mean difference: -6.5 · 95% CI -8.1 to -4.9
SecondaryPercentage of Participants Who Achieve ≥10% Body Weight Reduction

Percentage of participants who achieved ≥10% body weight reduction (observed values) was reported.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of participants15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percentage of Participants Who Achieve ≥10% Body Weight Reduction87.766.7
SecondaryPercentage of Participants Who Achieve ≥15% Body Weight Reduction

Percentage of participants who achieved ≥15% body weight reduction (observed values) was reported.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participants15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percentage of Participants Who Achieve ≥15% Body Weight Reduction71.745.0
SecondaryPercentage of Participants Who Achieve ≥20% Body Weight Reduction

Percentage of participants who achieved ≥20% body weight reduction (observed values) was reported.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥20% Body Weight Reduction
Percentage of participants15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percentage of Participants Who Achieve ≥20% Body Weight Reduction55.031.1
SecondaryPercentage of Participants Who Achieve ≥25% Body Weight Reduction

Percentage of participants who achieved ≥25% body weight reduction (observed values) was reported.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥25% Body Weight Reduction
Percentage of participants15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percentage of Participants Who Achieve ≥25% Body Weight Reduction36.518.6
SecondaryChange From Baseline in Waist Circumference in Centimeter

Change from baseline in waist circumference in centimeter was reported. LS mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeters
Change From Baseline in Waist Circumference in Centimeter
centimeters15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Change From Baseline in Waist Circumference in Centimeter-18.4 ± 0.61-13.0 ± 0.66
Statistical analysis
  • 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide · Ls mean difference: -5.4 · 95% CI -7.1 to -3.6
SecondaryPercentage of Participants Who Achieve ≥30% Body Weight Reduction

Percentage of participants who achieved ≥30% body weight reduction (observed values) was reported.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥30% Body Weight Reduction
Percentage of participants15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percentage of Participants Who Achieve ≥30% Body Weight Reduction23.08.2
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from baseline in BMI was reported. LS mean was determined using Mixed Model Repeated Measures (MMRM) model using Baseline + Sex + Pre diabetes status at randomization + Treatment + Time + Treatment\*Time(Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms per meter square
Change From Baseline in Body Mass Index (BMI)
kilograms per meter square15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Change From Baseline in Body Mass Index (BMI)-8.5 ± 0.24-6.0 ± 0.24
Statistical analysis
  • 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide · Ls mean difference: -2.6 · 95% CI -3.2 to -1.9
SecondaryPercent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide

Percent change from baseline in body weight comparing 15mg of Tirzepatide and 2.4 mg Semaglutide was reported. The treatment effect for tirzepatide versus semaglutide for percent change in body weight was also evaluated assuming that participants had stayed on treatment and reached the highest dose of treatment. LS mean was determined by MMRM model using Baseline + Sex + Pre diabetes status at randomization + Baseline BMI Group 1 + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide
Percent change15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
Percent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide-21.8 ± 0.60-15.4 ± 0.60
Statistical analysis
  • 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide · Ls mean difference: -6.4 · 95% CI -8.0 to -4.7

Adverse events

Collected over Baseline Up To 72 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
15 mg or MTD - Tirzepatide0/374 (0%)18/374 (4.8%)255/374 (68.2%)
2.4 mg or MTD - Semaglutide0/376 (0%)13/376 (3.5%)267/376 (71%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
Event15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
CholelithiasisHepatobiliary disorders2/3743/376
OsteoarthritisMusculoskeletal and connective tissue disorders2/3740/376
Bile duct stoneHepatobiliary disorders0/3742/376
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/243
Atrial fibrillationCardiac disorders1/3740/376
Sinus tachycardiaCardiac disorders1/3740/376
Incarcerated hiatus herniaGastrointestinal disorders1/3740/376
VolvulusGastrointestinal disorders1/3740/376
CholecystitisHepatobiliary disorders1/3740/376
Cholecystitis acuteHepatobiliary disorders1/3740/376
Most frequent other events
Showing 10 of 19
Most frequent other events
Event15 mg or MTD - Tirzepatide2.4 mg or MTD - Semaglutide
NauseaGastrointestinal disorders163/374167/376
ConstipationGastrointestinal disorders101/374107/376
DiarrhoeaGastrointestinal disorders88/37488/376
VomitingGastrointestinal disorders56/37480/376
Covid-19Infections and infestations51/37447/376
FatigueGeneral disorders39/37446/376
Upper respiratory tract infectionInfections and infestations32/37443/376
Gastrooesophageal reflux diseaseGastrointestinal disorders23/37440/376
EructationGastrointestinal disorders37/37429/376
Injection site reactionGeneral disorders32/3741/376

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)15 mg or MTD - Tirzepatide2.4 mg or MTD - SemaglutideTotal
Mean45.00 ± 12.9444.40 ± 12.7444.70 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)15 mg or MTD - Tirzepatide2.4 mg or MTD - SemaglutideTotal
Female242243485
Male132133265
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)15 mg or MTD - Tirzepatide2.4 mg or MTD - SemaglutideTotal
Hispanic or Latino93103196
Not Hispanic or Latino281273554
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)15 mg or MTD - Tirzepatide2.4 mg or MTD - SemaglutideTotal
American Indian or Alaska Native606
Asian11718
Native Hawaiian or Other Pacific Islander000
Black or African American7767144
White276295571
More than one race4711
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)15 mg or MTD - Tirzepatide2.4 mg or MTD - SemaglutideTotal
United States374376750
08

Study locations

32 sites
  • Cahaba Research
    Birmingham, Alabama 35242, United States
  • Cahaba Research - Pelham
    Pelham, Alabama 35124, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale, Florida 33009, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • Prime Health and Wellness/SKYCRNG
    Fayette, Mississippi 39069, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • WR-Clinsearch, LLC
    Chattanooga, Tennessee 37421, United States
  • The University of Texas Health Science Center at Houston
    Bellaire, Texas 77401, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Puerto Rico Medical Research
    Ponce, 00717, Puerto Rico
  • Wellness clinical Research Vega Baja
    Vega Baja, 00694, Puerto Rico
09

References and documents

Publications

  • Kitamoto T, Yoshino M, Shingaki T, Oura T, Gomez Valderas E, Dunn JP. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. Curr Med Res Opin. 2026 Jul 11:1-13. doi: 10.1080/03007995.2026.2695047. Online ahead of print. PubMed 42434924 ↗
  • Aronne LJ, Horn DB, Kokkinos AD, Falcon BL, Wang H, Hoffmann HT, Lee CJ, Dunn JP. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010. Epub 2026 Mar 20. PubMed 41865857 ↗
  • Mamas MA, Bays H, Li R, Upadhyay N, Irani T, Senyucel C, Dunn JP, Liu-Seifert H. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open. 2025 Sep 2;5(5):oeaf117. doi: 10.1093/ehjopen/oeaf117. eCollection 2025 Sep. PubMed 40980721 ↗
  • Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PubMed 40353578 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Nov 2024, 18 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Apr 21, 2023
StartActual
Apr 21, 2023
Primary completionActual
Nov 13, 2024
CompletionActual
Nov 13, 2024
Results first posted
Nov 26, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05822830
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Apr 21, 2023
Primary completion
Nov 13, 2024
Completion
Nov 13, 2024
Results posted
Nov 26, 2025
Last update
Nov 26, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion